Becton Dickinson (NYSE:BDX) sells basic healthcare products such as needles, surgical tools and syringes. It also sells products that are used in drug discovery and related lab functions. Sales aren't growing rapidly, but management has been able to control costs to boost earnings in the double digits annually. Going forward, investors should expect more than the same, and the stock looks very reasonably valued currently.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.

Recent Developments
Becton held an analyst day last fall, where it revealed details on its expected business trends over the next few years. The company sees growth in emerging markets, through the introduction of new products, and from acquisitions. It also plans to continue to cut costs and improve its cost structure through initiatives such as making its supply chain more efficient. On the new product front, it has continually reinvested sales into research and development. R&D expense is projected to triple to 18% by fiscal 2014 from 2009 levels of 6%.

The company's recent history suggests it should be able to continue to deliver on its goals. Since 2004, profit margins have steadily improved. Operating margins have increased from around 15% to above 20% over the last twelve months. Sales growth has been somewhat modest at 6.1% over the past five years, but the cost controls have allowed it to leverage this into annual profit growth close to 14%.

SEE: A Look At Corporate Profit Margins

Outlook and Valuation
For all of 2012, analysts project modest sales growth of 1.8% and total sales just below $8 billion. The current projections are for 2013 top-line growth of 3.6% and total sales of nearly $8.3 billion. Profit projections for these two annual periods are $5.70 and $6.19, respectively, and represent forward earnings multiples of 12.8 times and 11.8 times, respectively. This is well below Becton's five-year average of 16.4 and below the forward market multiple of 12.9.

The Bottom Line
Becton's rivals include CR Bard (NYSE:BCR), Baxter International (NYSE:BAX), CareFusion (NYSE:CFN) and PerkinElmer (NYSE:PKI). Only Baxter trades at a lower forward multiple for the coming year but has had some safety issues with some of its products. All over a high degree of sales stability, but Becton stands out for having one of the clearest growth strategies in the field as well as a solid track record of delivering on its goals.

At the time of writing, Ryan C. Fuhrmann did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Stock Analysis

    Hologic: An Activist Investment Analysis (HOLX)

    Read about a health care company that attracted activist investors Carl Icahn, Barry Rosenstein and Ralph Whitworth at the same time.
  2. Investing

    How To Make Sure Your Healthcare Costs Do Not Ruin Your Retirement

    The best proactive plan of action for a stable retirement is to understand medical costs, plan ahead, invest properly, and consider supplemental insurance.
  3. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  4. Personal Finance

    Zika Virus: Latest Advice on Staying Safe

    Zika has hit the U.S. Here’s a quick review of what’s known about the virus, how it spreads, who’s at highest risk and how to avoid it.
  5. Investing News

    Stryker Corporation: A Strong Capital Position

    A discussion on business operations, financials, valuation and growth trends for Stryker Corporation.
  6. Investing

    What Investors Need to Know About Returns in 2016

    Last year wasn’t a great one for investors seeking solid returns, so here are three things we believe all investors need to know about returns in 2016.
  7. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  8. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  9. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  10. Stock Analysis

    The Biggest Risks of Investing in Johnson & Johnson Stock (JNJ)

    Learn the largest risks to investing in Johnson & Johnson through fundamental analysis and other potential risks. Also discover how JNJ compares to its peers.
RELATED FAQS
  1. Does dental insurance cover implants?

    Dental implants have become a widely used procedure in dentistry. Despite their popularity, however, they tend to not be ... Read Full Answer >>
  2. Does dental insurance cover dentures?

    Most full dental insurance policies include some restorative coverage, usually meaning that up to 50% of the cost of dentures ... Read Full Answer >>
  3. Can CareCredit be used for family members?

    CareCredit has become a widely used option when it comes to paying for medical procedures, primarily procedures not typically ... Read Full Answer >>
  4. Can a Flexible Spending Account (FSA) be used for dental?

    Flexible Spending Accounts (FSAs) can be used to pay for dental expenses including deductibles and co-payments with pretax ... Read Full Answer >>
  5. Does dental insurance cover braces?

    Most regular dental plans cover little to none of the costs of braces. The primary focus of regular dental plans is prevention ... Read Full Answer >>
  6. Is dental insurance tax deductible?

    Dental insurance premiums may be tax deductible. To be deductible as a qualifying medical expense, the dental insurance must ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center